Other Nuclear Receptors – Targeting adenylate-forming enzymes with CXCL12 Inhibitors

We hypothesized that IP3-induced Ca2+ release during the initial phase would activate Pyk2

jamha April 5, 2022 0 Comments

We hypothesized that IP3-induced Ca2+ release during the initial phase would activate Pyk2. Both phosphorylation of Pyk2 and FAK leads to phosphorylation of paxillin at Tyr118 and association of phosphorylated paxillin with the GEF proteins p21-activated kinase (PAK) interacting exchange factor , ( and PIX) and DOCK 180. These GEF proteins stimulate Cdc42 leading to […]

To test for anergy, we adoptively transferred CD25neg CTV-labelled Bg2 cells into recipient mice and re-challenged them 28 days later with -gal721-739-pulsed bone marrow-derived DCs (BMDCs)

jamha February 6, 2022 0 Comments

To test for anergy, we adoptively transferred CD25neg CTV-labelled Bg2 cells into recipient mice and re-challenged them 28 days later with -gal721-739-pulsed bone marrow-derived DCs (BMDCs). chain and cathepsin L, but not H2-M, suggesting that they cannot load endogenous antigenic peptides onto MHC-II molecules. Importantly, LECs transfer -gal Mouse monoclonal to KLHL22 to dendritic cells, […]

Category: Other Nuclear Receptors

We hypothesized that IP3-induced Ca2+ release during the initial phase would activate Pyk2

To test for anergy, we adoptively transferred CD25neg CTV-labelled Bg2 cells into recipient mice and re-challenged them 28 days later with -gal721-739-pulsed bone marrow-derived DCs (BMDCs)

Recent Posts

Recent Comments

﻿We hypothesized that IP3-induced Ca2+ release during the initial phase would activate Pyk2

﻿To test for anergy, we adoptively transferred CD25neg CTV-labelled Bg2 cells into recipient mice and re-challenged them 28 days later with -gal721-739-pulsed bone marrow-derived DCs (BMDCs)

Recent Posts

Recent Comments

We hypothesized that IP3-induced Ca2+ release during the initial phase would activate Pyk2

To test for anergy, we adoptively transferred CD25neg CTV-labelled Bg2 cells into recipient mice and re-challenged them 28 days later with -gal721-739-pulsed bone marrow-derived DCs (BMDCs)